ELVN
Enliven Therapeutics, Inc.$46.37+5.97 (+14.79%)Prev Close$40.36·MCap$2.25B·P/E—·Vol5.35M·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
52
$22.36M
◆
Net Activity
Net Seller
$22.36M
●
Active Insiders
7
last 12 mo
Over the past 12 months, insider activity at Enliven Therapeutics, Inc. (ELVN) has been exclusively selling, with 0 insider purchases totaling $0.00 and 52 insider sales totaling $22.36M. The most recent insider transaction was by Kunkel Lori Anne (director), who sold $345.4K worth of shares on Jun 9, 2026. Enliven Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $2.25B.
ELVN Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 9, 2026 | Kunkel Lori Anne | director | Sell | 10,000 | $34.54 | $345.4K | 54,105 |
| May 20, 2026 | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | Sell | 5,000 | $39.79 | $199.0K | 26,525 |
| Apr 21, 2026 | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | Sell | 5,000 | $47.67 | $238.4K | 29,860 |
| Mar 27, 2026 | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | Sell | 40,000 | $35.10 | $1.40M | 25,000-62% |
| Mar 19, 2026 | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | Sell | 5,000 | $27.76 | $138.8K | 25,000 |
| Mar 11, 2026 | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | Sell | 40,000 | $30.07 | $1.20M | 25,000-62% |
| Mar 10, 2026 | Hohl Benjamin | officer: CHIEF FINANCIAL OFFICER | Sell | 10,000 | $29.58 | $295.8K | 51,000 |
| Feb 19, 2026 | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | Sell | 45,000 | $26.17 | $1.18M | 25,000-64% |
| Feb 19, 2026 | Heyman Richard A. | director | Sell | 1,230 | $26.18 | $32.2K | 22,647 |
| Feb 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 45,000 | $26.17 | $1.18M | 0 |
| Feb 17, 2026 | Heyman Richard A. | Director | Sell | 1,230 | $26.18 | $32.2K | 0 |
| Feb 10, 2026 | Lyssikatos Joseph P | officer: CHIEF SCIENTIFIC OFFICER | Sell | 5,000 | $29.04 | $145.2K | 740,188 |
| Feb 6, 2026 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 5,000 | $29.04 | $145.2K | 740,188 |
| Jan 22, 2026 | Heyman Richard A. | director | Sell | 1,230 | $26.75 | $32.9K | 24,595 |
| Jan 22, 2026 | Lyssikatos Joseph P | officer: CHIEF SCIENTIFIC OFFICER | Sell | 20,000 | $26.75 | $535.1K | 759,697 |
| Jan 20, 2026 | Heyman Richard A. | Director | Sell | 1,230 | $26.75 | $32.9K | 24,595 |
| Jan 20, 2026 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 20,000 | $26.75 | $535.1K | 759,697 |
| Jan 13, 2026 | Patel Anish | officer: CHIEF OPERATING OFFICER | Sell | 48,057 | $27.98 | $1.34M | 215,254 |
| Jan 12, 2026 | Heyman Richard A. | director | Sell | 12,300 | $25.02 | $307.8K | 29,392-30% |
| Jan 12, 2026 | Lyssikatos Joseph P | officer: CHIEF SCIENTIFIC OFFICER | Sell | 132,500 | $26.23 | $3.48M | 890,188 |
| Jan 9, 2026 | Patel Anish | CHIEF OPERATING OFFICER | Sell | 48,300 | $27.99 | $1.35M | 215,254 |
| Jan 8, 2026 | Heyman Richard A. | Director | Sell | 13,920 | $25.02 | $348.3K | 29,392-32% |
| Jan 8, 2026 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 132,500 | $26.23 | $3.48M | 890,188 |
| Dec 19, 2025 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 5,000 | $16.84 | $84.2K | 897,688 |
| Dec 8, 2025 | Patel Anish | CHIEF OPERATING OFFICER | Sell | 6,663 | $21.02 | $140.1K | 265,016 |
| Nov 19, 2025 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 12,500 | $22.33 | $279.2K | 903,180 |
| Nov 17, 2025 | Kintz Samuel | PRESIDENT AND CEO | Sell | 12,500 | $21.82 | $272.7K | 890,392 |
| Nov 7, 2025 | Patel Anish | CHIEF OPERATING OFFICER | Sell | 6,667 | $17.40 | $116.0K | 270,587 |
| Oct 20, 2025 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 12,500 | $22.08 | $276.0K | 915,188 |
| Oct 17, 2025 | Kintz Samuel | PRESIDENT AND CEO | Sell | 12,500 | $21.33 | $266.7K | 902,892 |
| Oct 7, 2025 | Patel Anish | CHIEF OPERATING OFFICER | Sell | 6,667 | $20.10 | $134.0K | 276,641 |
| Sep 29, 2025 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 3,250 | $20.40 | $66.3K | 23,000 |
| Sep 26, 2025 | Kintz Samuel | PRESIDENT AND CEO | Sell | 3,700 | $20.06 | $74.2K | 915,392 |
| Sep 26, 2025 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 4,000 | $20.25 | $81.0K | 927,688 |
| Sep 23, 2025 | Kintz Samuel | PRESIDENT AND CEO | Sell | 2,800 | $20.03 | $56.1K | 919,092 |
| Sep 23, 2025 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 1,500 | $20.03 | $30.0K | 931,688 |
| Sep 19, 2025 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 7,000 | $19.39 | $135.7K | 935,318 |
| Sep 17, 2025 | Kintz Samuel | PRESIDENT AND CEO | Sell | 6,000 | $19.29 | $115.7K | 922,892 |
| Sep 8, 2025 | Patel Anish | CHIEF OPERATING OFFICER | Sell | 6,667 | $20.24 | $135.0K | 283,308 |
| Aug 27, 2025 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 3,250 | $20.63 | $67.0K | 23,000 |
| Aug 19, 2025 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 12,500 | $19.86 | $248.2K | 947,688 |
| Aug 18, 2025 | Kintz Samuel | PRESIDENT AND CEO | Sell | 10,983 | $20.02 | $219.9K | 929,999 |
| Aug 7, 2025 | Patel Anish | CHIEF OPERATING OFFICER | Sell | 6,667 | $18.24 | $121.6K | 290,380 |
| Jul 28, 2025 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 3,250 | $20.46 | $66.5K | 23,065 |
| Jul 21, 2025 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 12,500 | $22.29 | $278.6K | 953,264 |
| Jul 17, 2025 | Kintz Samuel | PRESIDENT AND CEO | Sell | 12,500 | $22.52 | $281.5K | 948,742 |
| Jul 10, 2025 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 1,000 | $22.66 | $22.7K | 23,000 |
| Jul 7, 2025 | Patel Anish | CHIEF OPERATING OFFICER | Sell | 6,667 | $19.79 | $132.0K | 296,947 |
| Jun 27, 2025 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 3,250 | $20.91 | $68.0K | 23,198 |
| Jun 20, 2025 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 12,500 | $21.40 | $267.5K | 965,188 |
Showing 1–50 of 188
1 / 4
ELVN Insider Buying Activity
The following table shows recent insider purchases of Enliven Therapeutics, Inc. (ELVN) stock reported via SEC Form 4 filings.
No insider buying activity found for ELVN in the last 12 months.
ELVN Insider Selling Activity
The following table shows recent insider sales of Enliven Therapeutics, Inc. (ELVN) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 9, 2026 | Kunkel Lori Anne | director | Sell | 10,000 | $34.54 | $345.4K | 54,105 |
| May 20, 2026 | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | Sell | 5,000 | $39.79 | $199.0K | 26,525 |
| Apr 21, 2026 | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | Sell | 5,000 | $47.67 | $238.4K | 29,860 |
| Mar 27, 2026 | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | Sell | 40,000 | $35.10 | $1.40M | 25,000-62% |
| Mar 19, 2026 | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | Sell | 5,000 | $27.76 | $138.8K | 25,000 |
| Mar 11, 2026 | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | Sell | 40,000 | $30.07 | $1.20M | 25,000-62% |
| Mar 10, 2026 | Hohl Benjamin | officer: CHIEF FINANCIAL OFFICER | Sell | 10,000 | $29.58 | $295.8K | 51,000 |
| Feb 19, 2026 | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | Sell | 45,000 | $26.17 | $1.18M | 25,000-64% |
| Feb 19, 2026 | Heyman Richard A. | director | Sell | 1,230 | $26.18 | $32.2K | 22,647 |
| Feb 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 45,000 | $26.17 | $1.18M | 0 |
| Feb 17, 2026 | Heyman Richard A. | Director | Sell | 1,230 | $26.18 | $32.2K | 0 |
| Feb 10, 2026 | Lyssikatos Joseph P | officer: CHIEF SCIENTIFIC OFFICER | Sell | 5,000 | $29.04 | $145.2K | 740,188 |
| Feb 6, 2026 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 5,000 | $29.04 | $145.2K | 740,188 |
| Jan 22, 2026 | Heyman Richard A. | director | Sell | 1,230 | $26.75 | $32.9K | 24,595 |
| Jan 22, 2026 | Lyssikatos Joseph P | officer: CHIEF SCIENTIFIC OFFICER | Sell | 20,000 | $26.75 | $535.1K | 759,697 |
| Jan 20, 2026 | Heyman Richard A. | Director | Sell | 1,230 | $26.75 | $32.9K | 24,595 |
| Jan 20, 2026 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 20,000 | $26.75 | $535.1K | 759,697 |
| Jan 13, 2026 | Patel Anish | officer: CHIEF OPERATING OFFICER | Sell | 48,057 | $27.98 | $1.34M | 215,254 |
| Jan 12, 2026 | Heyman Richard A. | director | Sell | 12,300 | $25.02 | $307.8K | 29,392-30% |
| Jan 12, 2026 | Lyssikatos Joseph P | officer: CHIEF SCIENTIFIC OFFICER | Sell | 132,500 | $26.23 | $3.48M | 890,188 |
| Jan 9, 2026 | Patel Anish | CHIEF OPERATING OFFICER | Sell | 48,300 | $27.99 | $1.35M | 215,254 |
| Jan 8, 2026 | Heyman Richard A. | Director | Sell | 13,920 | $25.02 | $348.3K | 29,392-32% |
| Jan 8, 2026 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 132,500 | $26.23 | $3.48M | 890,188 |
| Dec 19, 2025 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 5,000 | $16.84 | $84.2K | 897,688 |
| Dec 8, 2025 | Patel Anish | CHIEF OPERATING OFFICER | Sell | 6,663 | $21.02 | $140.1K | 265,016 |
| Nov 19, 2025 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 12,500 | $22.33 | $279.2K | 903,180 |
| Nov 17, 2025 | Kintz Samuel | PRESIDENT AND CEO | Sell | 12,500 | $21.82 | $272.7K | 890,392 |
| Nov 7, 2025 | Patel Anish | CHIEF OPERATING OFFICER | Sell | 6,667 | $17.40 | $116.0K | 270,587 |
| Oct 20, 2025 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 12,500 | $22.08 | $276.0K | 915,188 |
| Oct 17, 2025 | Kintz Samuel | PRESIDENT AND CEO | Sell | 12,500 | $21.33 | $266.7K | 902,892 |
| Oct 7, 2025 | Patel Anish | CHIEF OPERATING OFFICER | Sell | 6,667 | $20.10 | $134.0K | 276,641 |
| Sep 29, 2025 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 3,250 | $20.40 | $66.3K | 23,000 |
| Sep 26, 2025 | Kintz Samuel | PRESIDENT AND CEO | Sell | 3,700 | $20.06 | $74.2K | 915,392 |
| Sep 26, 2025 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 4,000 | $20.25 | $81.0K | 927,688 |
| Sep 23, 2025 | Kintz Samuel | PRESIDENT AND CEO | Sell | 2,800 | $20.03 | $56.1K | 919,092 |
| Sep 23, 2025 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 1,500 | $20.03 | $30.0K | 931,688 |
| Sep 19, 2025 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 7,000 | $19.39 | $135.7K | 935,318 |
| Sep 17, 2025 | Kintz Samuel | PRESIDENT AND CEO | Sell | 6,000 | $19.29 | $115.7K | 922,892 |
| Sep 8, 2025 | Patel Anish | CHIEF OPERATING OFFICER | Sell | 6,667 | $20.24 | $135.0K | 283,308 |
| Aug 27, 2025 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 3,250 | $20.63 | $67.0K | 23,000 |
| Aug 19, 2025 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 12,500 | $19.86 | $248.2K | 947,688 |
| Aug 18, 2025 | Kintz Samuel | PRESIDENT AND CEO | Sell | 10,983 | $20.02 | $219.9K | 929,999 |
| Aug 7, 2025 | Patel Anish | CHIEF OPERATING OFFICER | Sell | 6,667 | $18.24 | $121.6K | 290,380 |
| Jul 28, 2025 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 3,250 | $20.46 | $66.5K | 23,065 |
| Jul 21, 2025 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 12,500 | $22.29 | $278.6K | 953,264 |
| Jul 17, 2025 | Kintz Samuel | PRESIDENT AND CEO | Sell | 12,500 | $22.52 | $281.5K | 948,742 |
| Jul 10, 2025 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 1,000 | $22.66 | $22.7K | 23,000 |
| Jul 7, 2025 | Patel Anish | CHIEF OPERATING OFFICER | Sell | 6,667 | $19.79 | $132.0K | 296,947 |
| Jun 27, 2025 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 3,250 | $20.91 | $68.0K | 23,198 |
| Jun 20, 2025 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | Sell | 12,500 | $21.40 | $267.5K | 965,188 |
ELVN Insiders
Similar Stocks to ELVN
VRTX
Vertex Pharmaceuticals Incorporated
$445.21+0.04%
$113.41B
REGN
Regeneron Pharmaceuticals, Inc.
$614.20+0.45%
$65.47B
ALNY
Alnylam Pharmaceuticals, Inc.
$283.35-2.09%
$40.46B
RVMD
Revolution Medicines, Inc.
$153.65+2.96%
$31.73B
UTHR
United Therapeutics Corporation
$542.43-0.54%
$23.12B
INSM
Insmed Incorporated
$98.28+1.64%
$20.41B
INCY
Incyte Corporation
$108.85+0.95%
$20.11B
MRNA
Moderna, Inc.
$50.18+1.06%
$18.89B